Another report showed that treatment of human breast cancer cells with the Hsp90 inhibitor 17DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin) facilitated TRAIL-induced apoptosis, and that RNAi-mediated gene knockdown of RIPK1 is sufficient to sensitize human breast tumor cells to TRAIL-induced apoptosis [32]. This evidence concerns the gene RIPK1 and breast carcinoma.